tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Pyxis Oncology price target raised to $7 from $5 at H.C. Wainwright
PremiumThe FlyPyxis Oncology price target raised to $7 from $5 at H.C. Wainwright
2M ago
Pyxis Oncology Reports Strong MICVO Data and Financing
Premium
Company Announcements
Pyxis Oncology Reports Strong MICVO Data and Financing
2M ago
Pyxis Oncology announces preliminary Phase 1 data for micvotabart pelidotin
Premium
The Fly
Pyxis Oncology announces preliminary Phase 1 data for micvotabart pelidotin
2M ago
Pyxis Oncology Reports Increased Losses Amid Development Focus
PremiumCompany AnnouncementsPyxis Oncology Reports Increased Losses Amid Development Focus
3M ago
Promising Efficacy of Pyxis Oncology’s MICVO in HNSCC Justifies Buy Rating Despite Financial Constraints
Premium
Ratings
Promising Efficacy of Pyxis Oncology’s MICVO in HNSCC Justifies Buy Rating Despite Financial Constraints
3M ago
Buy Rating for Pyxis Oncology: Promising Clinical Data and Strong Financial Position
Premium
Ratings
Buy Rating for Pyxis Oncology: Promising Clinical Data and Strong Financial Position
3M ago
Pyxis Oncology’s PYX-201 Study: A Promising Step in Solid Tumor Treatment
PremiumCompany AnnouncementsPyxis Oncology’s PYX-201 Study: A Promising Step in Solid Tumor Treatment
4M ago
Pyxis Oncology appoints Alex Kane as SVP, IR, capital markets
Premium
The Fly
Pyxis Oncology appoints Alex Kane as SVP, IR, capital markets
4M ago
Pyxis Oncology initiated with a Buy at Guggenheim
Premium
The Fly
Pyxis Oncology initiated with a Buy at Guggenheim
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100